Delek US (DK) Q1 2026 Earnings Transcript

Delek US reported a Q1 net loss of $201 million, or $3.34 per share, but adjusted net income was about $5 million and adjusted EBITDA was approximately $212 million, aided by record Logistics EBITDA of $132 million. Management raised its EOP target to at least $220 million annually, reaffirmed DKL 2026 EBITDA guidance of $520 million to $560 million, and signaled continued shareholder returns through dividends and buybacks. The call was constructive on refining margins and U.S. demand, while emphasizing that SRE/RIN compliance costs could reach $750 million in 2026 at $1.50 RIN pricing.

Analysis

The setup is less about a one-quarter beat and more about a multi-leg rerating catalyst: if the turnaround really removed the last major operational drag, then incremental cash flow should translate disproportionately into capital returns, not capex. That matters because refiners with near-term free cash flow inflection but unresolved regulatory overhangs often lag until the market believes buybacks/dividends are not being crowded out by maintenance spending. The cleaner the next two quarters run, the more likely DK trades like a cash-return story rather than a contested cyclical.

The hidden swing factor is not refining margin alone but the interaction between RIN/SRE policy and balance-sheet optics. If the company gets even partial relief, the market may capitalize that as recurring earnings rather than a one-time gain, which can support a much higher equity multiple; if relief disappoints, headline EBITDA still looks fine but distributable cash flow can be materially less attractive than bulls expect. That makes the equity more binary over the next 1-2 quarters than the call tone suggests.

DKL remains the higher-quality compounding vehicle because third-party mix and organic project completion reduce parent-level cyclicality; that should widen the valuation gap versus DK if the separation narrative progresses. The contrarian issue is that management is effectively arguing both for policy support and for structurally stronger product markets — if one of those legs weakens, the second-order effect is a reversion to mid-cycle refining economics faster than consensus models are likely assuming. In other words, the stock may be pricing in both higher throughput and higher regulatory help at once.

The market is probably underestimating how quickly capital allocation can accelerate after a turnaround quarter, but overestimating the durability of macro tailwinds if crack spreads normalize into summer. The best risk/reward is to own the asset with the cleanest deconsolidation path and hedge the more policy-sensitive parent exposure. Watch for a relief rally on any concrete SRE/EPA signal, but fade strength if there is no follow-through on buybacks within the next 30-60 days.

Key Decisions for Investors

• Long DKL / short DK pair trade into the next 1-3 months: DKL has the cleaner third-party cash flow story and deconsolidation optionality, while DK carries the heavier SRE and refining-margin policy risk; target relative outperformance if midstream multiples continue to re-rate.
• Initiate a tactical long DK only on pullbacks after any macro-driven selloff, with a 4-8 week horizon: the stock likely benefits most from post-turnaround cash conversion and buyback announcements, but upside should be sized smaller than DKL because policy risk can reprice quickly.
• Buy 2-3 month call spreads on DK rather than outright stock if looking for a catalyst trade: the setup is best for a rerating move tied to capital returns and EPA headlines, but the spread limits downside if RIN/SRE expectations get deferred.
• If already long refiners, rotate some exposure from broader refining names into DKL: the implied valuation gap between third-party midstream EBITDA and the parent’s cyclical earnings should narrow faster than the market expects over the next two quarters.
• Set a stop/trim trigger for DK on any sign that buybacks remain dormant for 30-60 days after turnaround completion: absent visible capital return, the market may revert to valuing DK on normalized margin rather than the promised cash-flow inflection.